



**Washington State Health Care Authority  
Prescription Drug Program**

626 8<sup>th</sup> Ave SE, Olympia, WA 98501 • 206-521-2029

<https://www.hca.wa.gov/about-hca/prescription-drug-program>

February 17, 2021

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority, Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective immediately:

<b>Antiplatelet reviewed 8/15/2018</b>		<b>Agency Coverage</b>	
<b>Ingredient Name</b>	<b>Label Name of Preferred Product</b>	<b>L&amp;I</b>	<b>UMP</b>
clopidogrel bisulfate	clopidogrel tablet	Not participating	Yes
The effect of this recommendation is no change to the Washington PDL.			

<b>Second Generation Antipsychotics reviewed 12/18/2019</b>		<b>Agency Coverage</b>	
<b>Ingredient Name</b>	<b>Label Name of Preferred Products</b>	<b>L&amp;I</b>	<b>UMP</b>
aripiprazole	Abilify Maintena <sup>®</sup> suspension reconstituted	No	Yes
	aripiprazole solution	Yes	Yes
	aripiprazole tablet	Yes	Yes
	aripiprazole ODT tablet dispersible	Yes	Yes
aripiprazole lauroxil	Aristada <sup>®</sup> injectable	No	Yes
	Aristada Initio <sup>®</sup> injectable	No	Yes
asenapine maleate	Saphris <sup>®</sup> sublingual	Yes	Yes
brexpiprazole	Rexulti <sup>®</sup> tablet	Yes	Yes
cariprazine HCL	Vraylar <sup>®</sup> capsule	Yes	Yes
clozapine	clozapine tablet	Yes	Yes
	clozapine ODT tablet dispersible	Yes	Yes
iloperidone	Fanapt <sup>®</sup> tablet	Yes	Yes
	Fanapt Titration Pack <sup>®</sup> tablet	Yes	Yes
lurasidone HCL	Latuda <sup>®</sup> tablet	Yes	Yes
olanzapine	olanzapine injectable	No	Yes
	olanzapine tablet	Yes	Yes
	olanzapine ODT tablet dispersible	Yes	Yes
olanzapine pamoate	Zyprexa Relprevv <sup>®</sup> suspension reconstituted	No	Yes
paliperidone	paliperidone ER tablet	Yes	Yes
paliperidone palmitate	Invega Sustenna <sup>®</sup> suspension	No	Yes
	Invega Trinza <sup>®</sup> suspension	No	Yes
quetiapine fumarate	quetiapine fumarate tablet	Yes	Yes
	quetiapine fumarate ER tablet	Yes	Yes
risperidone	risperidone solution	Yes	Yes

	risperidone tablet	Yes	Yes
	risperidone M-TAB tablet dispersible	Yes	Yes
	risperidone ODT tablet dispersible	Yes	Yes
risperidone microspheres	Risperdal Consta <sup>®</sup> suspension reconstituted	No	Yes
ziprasidone HCL	ziprasidone HCL capsule	Yes	Yes
ziprasidone mesylate	Geodon <sup>®</sup> solution	No	Yes
The effect of this recommendation is no change to the Washington PDL.			

Each agency will use the common PDL according to its benefit structure. You may view the current PDL on our [website](#).

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (206) 521-2029 or by email at [leta.evaskus@hca.wa.gov](mailto:leta.evaskus@hca.wa.gov).

Sincerely,



Donna Sullivan  
 Chief Pharmacy Officer  
 Clinical Quality and Care Transformation  
 Washington State Health Care Authority